PF-06438179/GP1111: An Infliximab Biosimilar

BioDrugs - United Kingdom
doi 10.1007/s40259-018-0310-5
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Crystal Structures of PF-06438179/GP1111, an Infliximab Biosimilar

BioDrugs
MedicineBiotechnologyPharmacology
2019English

Efficacious Transition From Reference Infliximab to Biosimilar Infliximab in Clinical Practice

International Journal of Rheumatic Diseases
Rheumatology
2019English

Pregnancy Outcomes in Women With Inflammatory Bowel Disease Treated With Biosimilar Infliximab

Gastroenterologie a Hepatologie
HepatologyGastroenterology
2018English

Physicochemical Characterization and Phase I Study of CMAB008, an Infliximab Biosimilar Produced by a Different Expression System

Drug Design, Development and Therapy
Drug DiscoveryPharmacologyPharmaceutical Science
2019English

Comparative Nonclinical Assessments of the Proposed Biosimilar PF-05280014 and Trastuzumab (Herceptin®)

BioDrugs
MedicineBiotechnologyPharmacology
2014English

Letter: Is There a Role for Infliximab Biosimilar in Patients With Inflammatory Bowel Disease With Secondary Loss of Response to Infliximab Innovator?

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2018English

GP2015: An Etanercept Biosimilar

BioDrugs
MedicineBiotechnologyPharmacology
2017English

AB0389 the Immunogenicity of Branded and Biosimilar Infliximab in Rheumatoid Arthritis According to Th9-Related Responses

2017English

Pms73 - Bright Future for the Use of Biosimilar Infliximab: Evidence-Based Analysis Using Healthcare Claim Database

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy